San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Dollar Stabilizes Amid Fragile US-Iran Ceasefire as Markets Watch Hormuz Strait 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
China Set to Exit Deflation Cycle in Early 2026, ANZ Analysts Say 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Gold Prices Rise on Weaker Dollar and Ceasefire Hopes 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Japan Consumer Confidence Drops Sharply Amid Rising Fuel Costs and Middle East Tensions 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Bank of America Maintains Forecast for Two Fed Rate Cuts in 2026 Despite Inflation Risks 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
U.S. Natural Gas Market Faces Short-Term Pressure but Long-Term Demand Surge 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Asian Currencies Hold Steady as Middle East Ceasefire Doubts Weigh on Markets 
Trump Slams Iran Over Strait of Hormuz Oil Restrictions Amid Fragile Ceasefire 
Celltrion revealed on Thursday, Sept. 23, that it would be supplying its rapid COVID-19 test kit called DiaTrust to the US government. This happened after the nation’s Department of Defense awarded the contract to them.
The South Korean biopharma stated that starting October 1st, its American division, Celltrion USA, will begin delivering the DiaTrust rapid test kits to 25,000 locations. The sites include nursing homes, coronavirus testing centers, and military facilities.
According to The Korea Herald, based on the agreement signed by Celltrion and the US Defense Logistics Agency, the United States could purchase additional kits if necessary. For the initial supply, the amount of the contract is said to be $626.61 million or 738.2 billion in Korean won.
Details for the initial order, like how many would be delivered was not disclosed. However, the publication stated that Bloomberg mentioned that the deal was for a total of 19 million DiaTrust test kits. With its contract with the DOD, Celltrion became the US’ largest supplier of rapid COVID-19 test kits.
“The fact that we were awarded a procurement contract by the DLA after having passed its strict screen process is a recognition of Celltrion’s technology and supply capability,” Celltrion USA chief executive officer, Bonjoong Kim, said in a press release. “With the COVID-19 pandemic still not showing signs of waning, we plan to focus on executing this contract as diligently as possible and further solidify the external credibility of Celltrion’s diagnostic test kits portfolio.”
It was added that the DiaTrust kits that will be delivered through this deal are point-of-care tests (POCT). This means that the COVID-19 rapid test will only be used in the presence of medical professionals. Apparently, this is for safety and to ensure that the process is done properly for more accurate results.
As per Pulse News, DiaTrust was jointly developed by Celltrion and Humasis, a Korean R&D company. The test kit was authorized by the US Food and Drug Administration (FDA) for emergency use last April.
Finally, Celltrion’s DiaTrust rapid COVID-19 kit is an antigen test that is used in medical settings. It can reveal the results on the spot since it only takes as little as 15 minutes to complete.
